Metformin Hydrochloride Extended - Release Tablets recalled over manufacturing violations
- Recall date
- June 2, 2020
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Official notice title
- Teva Pharmaceuticals USA recalls Metformin Hydrochloride Extended - Release Tablets, USP, 500 mg, a) 100 (NDC 62037-571-01) and b) 1,000 (NDC 62037-571-…
- Recall number
- D-1331-2020
- FDA classification
- Class II
- Brand / firm
- Teva Pharmaceuticals USA
- Sold / distributed
- Product was distributed throughout the United States, including Puerto Rico.
Why it was recalled
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
Metformin Hydrochloride Extended - Release Tablets, USP, 500 mg, a) 100 (NDC 62037-571-01) and b) 1,000 (NDC 62037-571-10) count bottles, Rx Only, Manufactured by: Watson Pharma Private Limited, Verna, Salcette Goa, Distributed by: Actavis Pharma, Inc., Parsippany, NJ
Get recall alerts
Free email alert whenever Teva Pharmaceuticals USA has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Teva Pharmaceuticals USA